Companies are born, they sprint, they thicken, they slow, and eventually they shrink. Nearly every expensive valuation error in our audited case library is a stage error: paying growth prices for a business that has stopped growing, or demanding dividend proof from one that is still mostly a story. Learn the stages and half your mistakes disappear before you make them.
Miss a quarter's revenue estimate and you lose a few percent. Miss a company's stage and you can lose most of your capital, because you were using the wrong ruler for years. The 2019 class of IPOs made this vivid. Lyft and Snap came public priced as if hypergrowth was guaranteed to continue for a decade, when both were still fighting for the right to exist profitably. Peloton was the reverse error in disguise: investors took a pandemic demand spike and treated it as a permanent promotion to a later, larger stage. When the company snapped back to its true position in the life cycle, the price followed, down more than 90% from the peak.
The same error runs the other way. In late 2022 the market priced Meta at $93 as if a business generating tens of billions in free cash flow had entered terminal decline. It had not changed stage. It had a spending problem inside a mature growth story, and when spending discipline returned, the price recovered multiples of that low. Both directions of the error, growth priced into fading firms and decline priced into healthy ones, come from the same blindness: not asking how old this company is in business years.
We work with six stages, and each leaves fingerprints you can read in any set of financials.
| Stage | Revenue | Cash flow | Where the value lives |
|---|---|---|---|
| 1. Startup | Tiny or none | Deeply negative | The idea and survival odds |
| 2. Young growth | Fast, from a small base | Negative | Proof the model works |
| 3. High growth | Fast, at scale | Turning positive | Growth and margin trajectory |
| 4. Mature growth | Above economy, slowing | Strongly positive | Returns on capital, the moat |
| 5. Mature stable | Tracks the economy | Large, distributed | Dividends and buybacks |
| 6. Decline | Shrinking | Positive but falling | Capital discipline on the way down |
Notice the pattern: as a company ages, its value migrates from imagination to execution to distribution. A stage 2 company is valued on whether the story can become real. A stage 4 company is valued on whether it can defend what is already real. A stage 6 company is valued almost entirely on whether management admits the decline and returns cash instead of burning it on reinvention fantasies.
Stages do not map neatly to years since founding. Some firms are middle-aged at ten and some are still adolescent at thirty. What matters is the combination of signals: revenue growth relative to the economy, the direction of margins, how much of every earned dollar must be reinvested just to stay in place, and whether cash is flowing in or out. When the fingerprints disagree with the market's assumed stage, that disagreement is the opportunity. When they disagree with your own assumed stage, that disagreement is the risk. Only about 30% of firms ever earn above their cost of capital, and most of those do it in a window between stages 3 and 5. Before and after that window, growth destroys value as easily as it creates it.
Here is the underappreciated reason broad indexes are so hard to beat: an index is a machine that plays the life cycle without sentiment. It admits companies as they rise into relevance, weights them more as they compound through their prime, and quietly shrinks and expels them as they decline. No loyalty, no averaging down, no thesis to defend. That machinery is how equities delivered roughly 6.5 to 7% real per year across two centuries even though the typical individual stock is a poor bet. Since 1926, roughly 4% of all listed stocks created the entire net wealth of the market above cash. The index holds the whole field precisely so it never misses those few, and it sells the dying without a meeting. A stock picker who refuses to think in stages is competing against an opponent that does nothing else.
Every stage has a natural owner, and misalignment between owner and stage is where accounts get hurt. Stages 1 and 2 belong to people who can accept that most positions go to zero and size them so the zeros do not matter. Stage 3 belongs to growth investors who will actually track cohort economics and competitive entry, not just the price chart. Stage 4 is the natural home of the quality compounder investor: this is where moats, returns on capital, and reinvestment discipline pay for decades. Stage 5 suits income-focused owners who want distribution, not drama. Stage 6 should be owned by almost nobody except specialists in wind-downs, because a shrinking business run by management in denial is a value trap with a dividend on top.
The classic mismatches write themselves: the income investor who buys a moonshot and sells in the first 40% drawdown, or the growth investor who keeps averaging down into a stage 6 melter because it looks statistically cheap. Neither lost to bad luck. Both lost to owning a stage their temperament could not hold.